Metastatic Breast Cancer - Pipeline Review, H2 2016

Date: December 7, 2016
Pages: 1096
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MB3A6A9FA2FEN
Leaflet:

Download PDF Leaflet

Metastatic Breast Cancer - Pipeline Review, H2 2016
Metastatic Breast Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Breast Cancer (Oncology) pipeline landscape.

Metastatic breast cancer (also called Stage IV or Advanced) is a stage of breast cancer in which cancer cells break away from the tumor in the breast, spread to other parts of the body and keep growing. Symptoms of metastatic breast cancer includes severe, progressive pain, and, less commonly, pathological fracture, erythema over the affected bone, swelling, jaundice, elevated liver enzymes, abdominal pain, loss of appetite, nausea, and vomiting. Other symptoms include fatigue, malaise and weight loss. Treatment includes hormone therapy, chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Breast Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 33, 81, 52, 2, 52, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 7 and 1 molecules, respectively.Metastatic Breast Cancer.

Metastatic Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Breast Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Breast Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Breast Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Breast Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Breast Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Metastatic Breast Cancer Overview
Therapeutics Development
Metastatic Breast Cancer - Therapeutics under Development by Companies
Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Breast Cancer - Pipeline Products Glance
Metastatic Breast Cancer - Products under Development by Companies
Metastatic Breast Cancer - Products under Investigation by Universities/Institutes
Metastatic Breast Cancer - Companies Involved in Therapeutics Development
Metastatic Breast Cancer - Therapeutics Assessment
Drug Profiles
Metastatic Breast Cancer - Dormant Projects 1033
Metastatic Breast Cancer - Discontinued Products 1049
Metastatic Breast Cancer - Product Development Milestones 1055
Appendix 1068

LIST OF TABLES

Number of Products under Development for Metastatic Breast Cancer, H2 2016
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Investigation by Universities/Institutes, H2 2016
Metastatic Breast Cancer - Pipeline by 3SBio Inc, H2 2016
Metastatic Breast Cancer - Pipeline by AB Science SA, H2 2016
Metastatic Breast Cancer - Pipeline by AbbVie Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Acceleron Pharma Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Advaxis Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
Metastatic Breast Cancer - Pipeline by Alteogen Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Amarna Therapeutics BV, H2 2016
Metastatic Breast Cancer - Pipeline by Ambrx Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Amgen Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Aphios Corp, H2 2016
Metastatic Breast Cancer - Pipeline by Arvinas Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Astellas Pharma Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H2 2016
Metastatic Breast Cancer - Pipeline by Bayer AG, H2 2016
Metastatic Breast Cancer - Pipeline by Beta Pharma Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Biocon Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Bionovis SA, H2 2016
Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
Metastatic Breast Cancer - Pipeline by Cantex Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Celgene Corp, H2 2016
Metastatic Breast Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Celltrion Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Clovis Oncology Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
Metastatic Breast Cancer - Pipeline by Curadis GmbH, H2 2016
Metastatic Breast Cancer - Pipeline by Curaxys SL, H2 2016
Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
Metastatic Breast Cancer - Pipeline by DexTech Medical AB, H2 2016
Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici SpA, H2 2016
Metastatic Breast Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by EirGenix Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Eisai Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H2 2016
Metastatic Breast Cancer - Pipeline by Ensol Biosciences Inc, H2 2016
Metastatic Breast Cancer - Pipeline by EOS Biosciences Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Epigen Biosciences Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Etubics Corp, H2 2016
Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by FibroGen Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Genelux Corp, H2 2016
Metastatic Breast Cancer - Pipeline by Genentech Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Gilead Sciences Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H2 2016
Metastatic Breast Cancer - Pipeline by GP Pharm SA, H2 2016
Metastatic Breast Cancer - Pipeline by GTx Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Hetero Drugs Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Humorigin Biotechnology Corp, H2 2016
Metastatic Breast Cancer - Pipeline by Immune Design Corp, H2 2016
Metastatic Breast Cancer - Pipeline by Immunomedics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Immunophotonics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Immupharma Plc, H2 2016
Metastatic Breast Cancer - Pipeline by Incyte Corp, H2 2016
Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H2 2016
Metastatic Breast Cancer - Pipeline by Kadmon Corp LLC, H2 2016
Metastatic Breast Cancer - Pipeline by Kancera AB, H2 2016
Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2016
Metastatic Breast Cancer - Pipeline by Mabion SA, H2 2016
Metastatic Breast Cancer - Pipeline by MacroGenics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by MandalMed Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Meabco A/S, H2 2016
Metastatic Breast Cancer - Pipeline by MedImmune LLC, H2 2016
Metastatic Breast Cancer - Pipeline by Medivation Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Merck & Co Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Merck KGaA, H2 2016
Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Merus NV, H2 2016
Metastatic Breast Cancer - Pipeline by MetaStat Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Morphotek Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Mycenax Biotech Inc, H2 2016
Metastatic Breast Cancer - Pipeline by NantKwest Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Natco Pharma Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H2 2016
Metastatic Breast Cancer - Pipeline by Neonc Technologies Inc, H2 2016
Metastatic Breast Cancer - Pipeline by NewLink Genetics Corp, H2 2016
Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Novartis AG, H2 2016
Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2016
Metastatic Breast Cancer - Pipeline by OBI Pharma Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Oncobiologics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016
Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
Metastatic Breast Cancer - Pipeline by Pfizer Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Pharma Mar SA, H2 2016
Metastatic Breast Cancer - Pipeline by PIQUR Therapeutics AG, H2 2016
Metastatic Breast Cancer - Pipeline by Plexxikon Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Polyphor Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Prescient Therapeutics Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Puma Biotechnology Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Radius Health Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016
Metastatic Breast Cancer - Pipeline by Samyang Holdings Corp, H2 2016
Metastatic Breast Cancer - Pipeline by Sanofi, H2 2016
Metastatic Breast Cancer - Pipeline by Seattle Genetics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Starpharma Holdings Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by SynCore Biotechnology Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Synthon Holdings BV, H2 2016
Metastatic Breast Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Tocagen Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Transgene Biotek Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Tyme Technologies Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016
Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Vyriad Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Wilex AG, H2 2016
Metastatic Breast Cancer - Pipeline by WntResearch AB, H2 2016
Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2016
Metastatic Breast Cancer - Pipeline by Zymeworks Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Metastatic Breast Cancer - Dormant Projects, H2 2016 1060
Metastatic Breast Cancer - Dormant Projects (Contd..1), H2 2016 1061
Metastatic Breast Cancer - Dormant Projects (Contd..2), H2 2016 1062
Metastatic Breast Cancer - Dormant Projects (Contd..3), H2 2016 1063
Metastatic Breast Cancer - Dormant Projects (Contd..4), H2 2016 1064
Metastatic Breast Cancer - Dormant Projects (Contd..5), H2 2016 1065
Metastatic Breast Cancer - Dormant Projects (Contd..6), H2 2016 1066
Metastatic Breast Cancer - Dormant Projects (Contd..7), H2 2016 1067
Metastatic Breast Cancer - Dormant Projects (Contd..8), H2 2016 1068
Metastatic Breast Cancer - Dormant Projects (Contd..9), H2 2016 1069
Metastatic Breast Cancer - Dormant Projects (Contd..10), H2 2016 1070
Metastatic Breast Cancer - Dormant Projects (Contd..11), H2 2016 1071
Metastatic Breast Cancer - Dormant Projects (Contd..12), H2 2016 1072
Metastatic Breast Cancer - Dormant Projects (Contd..13), H2 2016 1073
Metastatic Breast Cancer - Dormant Projects (Contd..14), H2 2016 1074
Metastatic Breast Cancer - Dormant Projects (Contd..15), H2 2016 1075
Metastatic Breast Cancer - Discontinued Products, H2 2016 1076
Metastatic Breast Cancer - Discontinued Products (Contd..1), H2 2016 1077
Metastatic Breast Cancer - Discontinued Products (Contd..2), H2 2016 1078
Metastatic Breast Cancer - Discontinued Products (Contd..3), H2 2016 1079
Metastatic Breast Cancer - Discontinued Products (Contd..4), H2 2016 1080
Metastatic Breast Cancer - Discontinued Products (Contd..5), H2 2016 1081

LIST OF FIGURES

Number of Products under Development for Metastatic Breast Cancer, H2 2016
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Breast Cancer - Pipeline Review, H2 2016 US$ 2,500.00 Dec, 2016 · 3149 pages
Metastatic Liver Cancer - Pipeline Review, H2 2015 US$ 2,000.00 Oct, 2015 · 58 pages
Metastatic Pancreatic Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 416 pages

Ask Your Question

Metastatic Breast Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: